Peptide Immunotherapy; Short but Long Lasting?

Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–75.

Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25.

Larche M. Peptide immunotherapy for allergic diseases. Allergy. 2007;62(3):325–31.

Moldaver D, Larche M. Immunotherapy with peptides. Allergy. 2011;66(6):784–91.

Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med. 2005;2(3):e78.

van de Veen W, Stanic B, Yaman G, Wawrzyniak M, Söllner S, Akdis DG, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131(4):1204–12.

Shamji MH, Ljørring C, Francis JN, Calderon MA, Larché M, Kimber I, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67(2):217–26.

Kiel MA, Röder E, Gerth van Wijk RG, Al MJ, Hop WCJ, Rutten-van Mölken MPMH. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132:353–60. A recent study providing real-life compliance data from registry data on over 6,000 allergic individuals prescribed either subcutaneous or sublingual immunotherapy. The article highlights the extremely poor compliance with these forms of therapy.

Calabria CW, Dice JP, Hagan LL. Prevalence of positive skin test responses to 53 allergens in patients with rhinitis symptoms. Allergy Asthma Proc. 2007;28(4):442–8.

Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116(2):377–83.

Taylor WW, Ohman Jr JL, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol. 1978;61:283–7.

Ohman JL, Findlay SR, Leitermann KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol. 1984;74(3 Pt 1):230–9.

Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89-97, 97.e1-14. A recent study describing the development of the first SPIRE therapy, Cat-PAD, including the results of the first-into-man Phase 2a clinical trial.

Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Expert Opin Investig Drugs. 2013;22(10):1347–57. A recent study describing results from the first Phase 2b clinical trial of Cat-PAD.

Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103-9.e1-7. A key recent article describing enduring clinical efficacy of a short course of peptide immunotherapy given over a three month period. Despite no further treatment for nine months, a persistent treatment effect was observed one year after initiation of the study.

Couroux P, Patel D, Armstrong K, Larché M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015; .doi: 10.1111/cea.12488

Hafner RP, Couroux P, Armstrong K, et al. Total nasal symptom scores are reduced in an EEC model of cat allergy two years after administration of four doses of Cat-PAD. Allergy. 2013;68(97):647–8.

Haumann B, Couroux P, Armstrong K, et al. Cat-PAD demonstrates sustained, consistent treatment effect on allergic rhinoconjunctivitis in individual cat allergic patients 1 and 2 years after four intradermal injections. Allergy. 2013;68(97):70.

Larche M, Hickey P, Hebert J, et al. Safety and tolerability of escalating doses of house dust mite- peptide antigen desensitization (HDM-PAD). J Allergy Clin Immunol. 2013;131(2):AB37.

Hafner R, Couroux P, Armstrong K, et al. Persistent treatment effect achieved at one year after four doses of der p derived synthetic peptide immuno-regulatory epitopes in an exposure chamber model of house dust mite allergy. J Allergy Clin Immunol. 2014;133(2):AB289.

Hafner RP, Couroux P, Armstrong K, et al. Four doses of Der p derived synthetic peptide immuno-regulatory epitopes over 3 months results in a persistent treatment effect at 1 year on symptoms of house dust mite allergy. Allergy. 2014;69(99):31–2.

Ellis AK, Frankish CW, Armstrong K, et al. Treatment with synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a substantial reduction in grass allergy symptoms in the environmental exposure unit. J Allergy Clin Immunol. 2014;133(2):AB290.

Ellis AK, Frankish CW, Armstrong K, et al. A short course of synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a reduction in grass allergy symptoms. Allergy. 2014;69(99):32.